Iterum Therapeutics (ITRM)
NASDAQ: ITRM
· Real-Time Price · USD
0.74
-0.00 (-0.40%)
At close: Sep 26, 2025, 10:59 AM
-0.40% (1D)
| Bid | 0.73 |
| Market Cap | 32.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -24.08M |
| EPS (ttm) | -0.81 |
| PE Ratio (ttm) | -0.91 |
| Forward PE | -2.89 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 0.74 |
| Volume | 92,505 |
| Avg. Volume (20D) | 838,115 |
| Open | 0.75 |
| Previous Close | 0.74 |
| Day's Range | 0.73 - 0.77 |
| 52-Week Range | 0.61 - 3.02 |
| Beta | 3.04 |
| Ex-Dividend Date | n/a |
About ITRM
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ITRM
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ITRM stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts5 months ago
-15.87%
Iterum Therapeutics shares are trading lower after...
Unlock content with
Pro Subscription
11 months ago
+60.68%
Iterum Therapeutics shares are trading higher after the FDA approved the company's new drug application for ORLYNVAH for the treatment of uncomplicated urinary tract infections.
